Collegetium Pharma Elects New Directors, Updates Exec Pay
Ticker: COLL · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1267565
| Field | Detail |
|---|---|
| Company | Collegium Pharmaceutical, Inc (COLL) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $50,000, $412,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-of-directors
TL;DR
Collegetium Pharma adds 2 directors, inks new pay deals for CEO & CFO.
AI Summary
Collegium Pharmaceutical, Inc. announced on February 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Paul J. Maddon and Ms. Susan J. Froehlich, to its Board of Directors, effective February 3, 2025. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Michael Dean, and Chief Financial Officer, Steven Hearne, detailing their compensation packages.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and executive compensation adjustments, which are common and generally do not indicate significant new risks.
Key Players & Entities
- Collegium Pharmaceutical, Inc. (company) — Registrant
- Dr. Paul J. Maddon (person) — Newly elected director
- Ms. Susan J. Froehlich (person) — Newly elected director
- Michael Dean (person) — Chief Executive Officer
- Steven Hearne (person) — Chief Financial Officer
- February 3, 2025 (date) — Effective date of director elections and employment agreements
FAQ
Who were the newly elected directors for Collegium Pharmaceutical, Inc.?
Dr. Paul J. Maddon and Ms. Susan J. Froehlich were elected to the Board of Directors.
When were the new directors elected?
The new directors were elected effective February 3, 2025.
Which executive officers entered into new employment agreements?
The Chief Executive Officer, Michael Dean, and the Chief Financial Officer, Steven Hearne, entered into new employment agreements.
What is the principal executive office address for Collegium Pharmaceutical, Inc.?
The principal executive offices are located at 100 Technology Center Drive, Suite 300, Stoughton, MA 02072.
What is the filing date of this Form 8-K?
The Form 8-K was filed on February 5, 2025.
Filing Stats: 903 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2025-02-05 08:05:30
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
- $50,000 — will receive an annual cash retainer of $50,000 for her service on the Board, prorated
- $412,500 — the Company with a grant date value of $412,500, representing an initial equity award a
Filing Documents
- tm255440d1_8k.htm (8-K) — 24KB
- 0001104659-25-009384.txt ( ) — 195KB
- coll-20250203.xsd (EX-101.SCH) — 3KB
- coll-20250203_lab.xml (EX-101.LAB) — 33KB
- coll-20250203_pre.xml (EX-101.PRE) — 22KB
- tm255440d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 3, 2025, the board of directors (the "Board") of Collegium Pharmaceutical, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025 (the "Effective Date"). Ms. Lurker will serve an initial term expiring at the Company's 2025 Annual Meeting of Shareholders or until her successor is duly elected and qualified or until her earlier resignation, death or removal. Ms. Lurker, 67, has served as the Vice Chair of the board of directors of EyePoint Pharmaceuticals, Inc. ("EyePoint") since July 2023. Prior to this role, Ms. Lurker served as President and Chief Executive Officer of EyePoint from 2016 to July 2023. Prior to EyePoint, Ms. Lurker served as President and Chief Executive Officer and a director of PDI, Inc. (now Interpace Diagnostics Group, Inc.) (OTC: IDXG), a publicly-traded healthcare commercialization company, and as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. Prior to that, Ms. Lurker held various senior positions at other leading pharmaceutical companies including Pharmacia Corporation (now a part of Pfizer, Inc.), ImpactRx and Bristol-Myers Squibb Company. Ms. Lurker currently serves on the board of directors of Alkermes plc (Nasdaq: ALKS), Altasciences, LLC, a private contract research organization and National Sanitation Foundation, a not-for-profit organization dedicated to improving human health through quality standards. She previously served on the boards of directors of the Cancer Treatment Centers of America, Aquestive Therapeutics, Inc., X4 Pharmaceuticals, Inc., Auxi
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 5, 2025 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer